ストックスクリーナーアプリを入手
215.95
2.13%
-4.71
前日終値:
$220.66
開ける：
$220
24時間の取引高:
1.19M
Relative Volume:
0.99
時価総額：
$36.39B
収益：
$2.75B
当期純損益:
$714.14M
株価収益率:
49.87
EPS:
4.33
ネットキャッシュフロー:
$1.09B
1週間 パフォーマンス:
+2.52%
1か月 パフォーマンス:
-8.87%
6か月 パフォーマンス:
-0.49%
1年 パフォーマンス:
+8.41%
1日の値動き範囲:
$215.44
$220.82
1週間の範囲:
$208.34
$225.21
52週間の値動き範囲:
$170.25
$258.93
Veeva Systems Inc Stock (VEEV) Company Profile
VEEV を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VEEV
Veeva Systems Inc
|
215.95 | 36.39B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
53.21 | 9.87B | 516.85M | 174.11M | 217.38M | 0.87 |
|
TEM
Tempus Ai Inc
|
40.45 | 7.46B | 640.44M | -743.28M | -206.93M | -11.29 |
|
HQY
Healthequity Inc
|
84.52 | 7.21B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
36.45 | 6.30B | 906.14M | -52.62M | 89.62M | -0.3621 |
Veeva Systems Inc Stock (VEEV) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-01-23 | ダウングレード | Goldman | Buy → Sell |
| 2024-12-20 | 開始されました | Stephens | Overweight |
| 2024-12-04 | 開始されました | Mizuho | Outperform |
| 2024-11-19 | 開始されました | Scotiabank | Sector Perform |
| 2024-10-08 | 開始されました | Exane BNP Paribas | Outperform |
| 2024-08-27 | 繰り返されました | Citigroup | Buy |
| 2024-07-09 | 開始されました | BTIG Research | Buy |
| 2023-10-25 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-10-13 | 開始されました | Jefferies | Buy |
| 2023-06-28 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-06-01 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-17 | ダウングレード | Truist | Buy → Hold |
| 2023-02-23 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-04 | アップグレード | Barclays | Equal Weight → Overweight |
| 2022-12-06 | 開始されました | Cowen | Market Perform |
| 2022-12-02 | 繰り返されました | Needham | Buy |
| 2022-10-31 | 開始されました | Wells Fargo | Equal Weight |
| 2022-10-19 | アップグレード | JP Morgan | Underweight → Neutral |
| 2022-09-16 | 開始されました | KeyBanc Capital Markets | Overweight |
| 2022-07-27 | 開始されました | Oppenheimer | Outperform |
| 2022-06-23 | 開始されました | Goldman | Buy |
| 2022-06-21 | 再開されました | Guggenheim | Buy |
| 2022-03-03 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-01-28 | 開始されました | Truist | Buy |
| 2022-01-07 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-06 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-16 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | 再開されました | Stifel | Buy |
| 2021-09-02 | 繰り返されました | BofA Securities | Buy |
| 2021-09-02 | 繰り返されました | JMP Securities | Mkt Outperform |
| 2021-09-02 | 繰り返されました | Needham | Buy |
| 2021-09-02 | 繰り返されました | UBS | Neutral |
| 2021-07-21 | 開始されました | Cowen | Outperform |
| 2021-03-31 | アップグレード | UBS | Sell → Neutral |
| 2021-01-07 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2020-12-09 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2020-10-14 | 再開されました | UBS | Sell |
| 2020-08-28 | 繰り返されました | Needham | Buy |
| 2020-07-23 | 開始されました | FBN Securities | Outperform |
| 2020-07-07 | 開始されました | Stephens | Overweight |
| 2020-06-08 | 開始されました | Citigroup | Buy |
| 2020-05-29 | 繰り返されました | Needham | Buy |
| 2020-04-13 | 開始されました | SVB Leerink | Mkt Perform |
| 2020-02-19 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-14 | 開始されました | Piper Sandler | Overweight |
| 2020-01-13 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2019-11-27 | 繰り返されました | Canaccord Genuity | Hold |
| 2019-09-26 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-08-28 | 繰り返されました | Needham | Buy |
| 2019-06-07 | 開始されました | Goldman | Neutral |
| 2019-05-30 | 繰り返されました | BofA/Merrill | Buy |
| 2019-05-30 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2019-05-24 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2019-04-17 | 繰り返されました | Needham | Buy |
| 2019-02-27 | 繰り返されました | Needham | Buy |
すべてを表示
Veeva Systems Inc (VEEV) 最新ニュース
Wall Street Bulls Look Optimistic About Veeva (VEEV): Should You Buy? - Yahoo Finance
Don't Try to Time the Market: These 2 Stocks Are Buys Regardless of What Happens Next - The Motley Fool
Life Science Data Needs an Upgrade: Veeva Has Answers - Fierce Pharma
Veeva Systems: Substantially Overvalued As Growth Slows (NYSE:VEEV) - Seeking Alpha
Here is What to Know Beyond Why Veeva Systems Inc. (VEEV) is a Trending Stock - Yahoo Finance
Veeva Systems (NYSE:VEEV) Partners With Flatiron To Enhance Clinical Trial Data Efficiency - Yahoo Finance
Flatiron Health Joins Veeva’s Product Partner Program to Accelerate Oncology Clinical Research - Yahoo Finance
Q4 Earnings Outperformers: Veeva Systems (NYSE:VEEV) And The Rest Of The Vertical Software Stocks - Yahoo Finance
Veeva Systems (VEEV) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Veeva Systems’ chief customer officer sells $265,168 in stock By Investing.com - Investing.com India
Veeva Systems’ chief customer officer sells $265,168 in stock - Investing.com
4 Ways Top Sponsors Build Strong and Sustainable Site Relationships - Veeva
Investors Interested In Veeva Systems Inc.'s (NYSE:VEEV) Earnings - simplywall.st
Improve Safety Outputs, Oversight, and Data Quality with In-house Pharmacovigilance Solution - Veeva
Veeva (VEEV) Moves 3.7% Higher: Will This Strength Last? - Nasdaq
eClinical Solutions Market Top PlayersMedidata, Veeva Systems, Iqvia Inc., Icon Plc, Signant Health. - openPR.com
ACELYRIN Optimizes the Sponsor-CRO Data Flow with a Centralized Clinical Data Workbench - Veeva
Veeva Systems director Timothy Cabral sells $841,734 in stock By Investing.com - Investing.com Canada
Veeva Systems director Timothy Cabral sells $841,734 in stock - Investing.com
Veeva Systems (VEEV) Gains As Market Dips: What You Should Know - Yahoo Finance
Why Is Veeva (VEEV) Down 6.2% Since Last Earnings Report? - Yahoo Finance
Veeva Systems (VEEV) Benefited in Q4 From Strong Execution - Insider Monkey
Veeva Systems Inc. (VEEV) is Attracting Investor Attention: Here is What You Should Know - MSN
The Zacks Rank Explained: How to Find Strong Buy Medical Stocks - Yahoo Finance
Best Momentum Stocks to Buy for April 3rd - TradingView
Veeva Systems Inc. (NYSE:VEEV) Receives $256.52 Average PT from Brokerages - MarketBeat
Veeva Systems SVP sells shares worth $178,019 - Investing.com Australia
Wall Street Analysts Think Veeva (VEEV) Is a Good Investment: Is It? - MSN
Veeva Systems SVP sells shares worth $178,019 By Investing.com - Investing.com Canada
We Think Veeva Systems' (NYSE:VEEV) Profit Is Only A Baseline For What They Can Achieve - Yahoo
VEEV Stock Slips Despite New Research Site Clinical Trial System - Yahoo Finance
How UCB and Other Biopharmas Made the Case for Safety Transformation - Veeva
Aligning Medical & Commercial Teams to Drive Product Adoption - Veeva
Veeva Systems (NYSE:VEEV) Unveils New CTMS for Efficient Clinical Trial Management - Yahoo Finance
Veeva Announces Research Site Clinical Trial Management System - Contract Pharma
5 Momentum Stocks to Buy for April Despite a Disappointing March - TradingView
Sell Rating for Veeva Systems Amid Volatile Macroeconomic Conditions and Industry Risks - TipRanks
EVERSANA joins with Veeva in push to 'pharmatise AI' - pharmaphorum
EVERSANA Joins Veeva AI Partner Program - PR Newswire
Top Stock Picks for Week of March 31, 2025 - TradingView
Veeva Systems’ SWOT analysis: cloud software leader faces industry headwinds - Investing.com
Here's Why You Should Add Veeva Systems Stock to Your Portfolio Now - MSN
China Expansion Helps Fuel This AI-Powered Cloud Stock In Rough Market - Investor's Business Daily
What Does the Market Think About Veeva Systems? - Benzinga
Verve: Embracing Digital-First Quality - Veeva
Exponential Growth Expected for Clinical Data Management - openPR
Veeva Systems, Inc. is hiring: Creative Operations Manager in New York - Mediabistro
With EPS Growth And More, Veeva Systems (NYSE:VEEV) Makes An Interesting Case - simplywall.st
Electronic Trial Master File (eTMF) Systems Market Size, Trends - openPR
Here's How Much a $1000 Investment in Veeva Systems Made 10 Years Ago Would Be Worth Today - Yahoo Finance
Decentralized Clinical Trials Market to Expand Rapidly Growth - openPR
Veeva Systems Inc (VEEV) 財務データ
収益
当期純利益
現金流量
EPS
0.81%
1.00%
大文字化:
|
ボリューム (24 時間):